SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Drug Safety Risks - Hagens Berman

SAN FRANCISCO, April 30, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025 (the "Class Period"), and suffered significant losses to submit your losses now.